Monitoring breast cancer response to neoadjuvant chemotherapy with ultrasound signal statistics and integrated backscatter

TL;DR

This study introduces a novel ultrasound signal analysis method using backscatter statistics to early monitor breast cancer response to chemotherapy, potentially improving personalized treatment adjustments.

Contribution

The paper demonstrates the first use of backscatter statistics for assessing neoadjuvant chemotherapy effects in breast cancer, showing promising predictive accuracy.

Findings

Significant differences in ultrasound markers after 2-5 chemotherapy doses.

High predictive accuracy (AUC up to 0.91) for response after 3 doses.

Ultrasound backscatter parameters can effectively monitor treatment response.

Abstract

Monitoring Neoadjuvant chemotherapy (NAC) effects is necessary to capture resistant patients and stop or change treatment. The aim of this study was to assess the tumor response at an early stage, after the first doses of the NAC, based on the variability of the backscattered ultrasound energy, and backscatter statistics. The backscatter statistics has not previously been used to monitor NAC effects. The B-mode ultrasound images and raw radio frequency data from breast tumors were obtained using an ultrasound scanner before chemotherapy and 1 week after each NAC cycle. Twenty-four malignant breast cancers, qualified for neoadjuvant treatment before surgery, were included in the study. The shape parameter of the homodyned K distribution and integrated backscatter, along with the tumor size in the longest dimension, were determined based on ultrasound data and used as markers for NAC response. Cancer tumors were assigned to responding and non-responding groups, according to histopathological evaluation, which was a reference in assessing the utility of markers. Statistical analysis was performed to rate the ability of markers to predict NAC response based on data obtained after subsequent therapeutic doses. Statistically significant differences between groups were obtained after 2, 3, 4, and 5 doses of NAC for quantitative ultrasound markers and after 5 doses for the assessment based on maximum tumor dimension. After the second and third NAC courses the marker, which was a linear combination of both quantitative ultrasound parameters, was characterized by an AUC of 0.82 and 0.91, respectively. The introduction of statistical parameters of ultrasonic backscatter to monitor the effects of chemotherapy can increase the effectiveness of monitoring and contribute to a better personalization of NAC therapy.